Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$443.6m

Aura Biosciences Past Earnings Performance

Past criteria checks 0/6

Aura Biosciences's earnings have been declining at an average annual rate of -24.6%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-24.6%

Earnings growth rate

86.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-47.6%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Sep 17

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Sep 11
We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 03
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Revenue & Expenses Breakdown

How Aura Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:AURA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-832271
30 Jun 240-812170
31 Mar 240-792068
31 Dec 230-762065
30 Sep 230-712058
30 Jun 230-681954
31 Mar 230-631948
31 Dec 220-591842
30 Sep 220-551737
30 Jun 220-521532
31 Mar 220-511329
31 Dec 210-461025
30 Sep 210-40821
30 Jun 210-33617
31 Mar 210-29516
31 Dec 200-30418

Quality Earnings: AURA is currently unprofitable.

Growing Profit Margin: AURA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AURA is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare AURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: AURA has a negative Return on Equity (-47.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies